ADVERTISEMENT

ACIP immunization update

The Journal of Family Practice. 2011 May;60(05):271-273
May 1, 2011|Family Medicine
Doug Campos-Outcalt, MD, MPA
Author and Disclosure Information

Doug Campos-Outcalt, MD, MPA
Department of Family and Community Medicine, University of Arizona, College of Medicine, Phoenix
dougco@u.arizona.edu

ACIP’s recommendations stress the need to protect vulnerable populations from rising rates of pertussis infection, improve health care personnel Tdap immunization rates, and increase the number of MCV4 doses for those at high risk of meningitis.

More schedule details in the footnotes. The new schedules contain a number of clarifications in the footnotes that:1,11

  • explain the spacing of the 3-dose primary series for hepatitis B vaccine (HepB) for infants if they do not receive a dose immediately after birth
  • clarify the circumstances in which children younger than age 9 need 2 doses of influenza vaccine
  • describe the availability of both a quadrivalent human papillomavirus vaccine (HPV4) and a bivalent vaccine (HPV2) to prevent precancerous cervical lesions and cancer
  • list the option for using HPV4 for males for the prevention of genital warts.

TABLE 2
Meningococcal conjugate vaccine recommendations by risk group, ACIP 2010

Risk groupPrimary seriesBooster dose
Individuals ages 11-18 years1 dose, preferably at age 11 or 12 years
  • Age 16 years, if primary dose given at age 11 or 12 years
  • Age 16-18 years, if primary dose given at age 13-15 years
  • No booster needed if primary dose given at ≥16 years
HIV-infected individuals ages 11-18 years2 doses, 2 months apart
  • Age 16 years, if primary series given at age 11 or 12 years
  • Age 16-18 years, if primary series given at age 13-15 years
  • No booster needed if primary series given at ≥16 years
Individuals ages 2-55 years with persistent complement component deficiency such as C5-C9, properdin, or factor D, or functional or anatomic asplenia2 doses, 2 months apart
  • Every 5 years
  • At the earliest opportunity if primary series was 1 dose, then every 5 years thereafter
Individuals ages 2-55 years with prolonged increased risk of exposure, such as microbiologists routinely working with Neisseria meningitidis and travelers to, or residents of, countries where meningococcal disease is hyperendemic or epidemic1 dose
  • After 3 years for individuals ages 2-6 years
  • After 5 years for individuals ≥7 years if still at increased risk
Source: Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2011.10

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT